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© 2011 The Japan Society of Histochemistry and Cy- This study was designed to clarify the mechanism of the mammalian target of rapamycin
(mTOR)-hypoxia inducible factor-1 (HIF-1) pathway using the cultured cell strain derived
from human ovarian clear cell adenocarcinoma (CCA). Everolimus (a derivative of rapamycin)-
treated cells and non-treated cells did not show any difference in mTOR expression. But,
phosphorylated-mTOR (p-mTOR) expression significantly decreased in the treated cells, and
mTOR-related factors such as phosphorylated-4E-BP1 (p-4E-BP1), HIF-1α, and vascular
endothelial growth factor (VEGF) in the downstream region of mTOR revealed a marked
decrease in expression. The analysis of influences of the drug on the HIF-1α degradation
system showed an increase in von-Hippel Lindau (VHL) expression in the treated cells.
Increase of cleaved caspase-3, one of key factors involved in apoptosis, was also shown in
the treated cells. In the next step, using nude mice implanted with RMG-1 cells, a decrease
in tumor size was demonstrated in 4 of the 7 mice which were orally administered with
everolimus. As a result, it was suggested that everolimus administration would be helpful as
an anti-tumor therapy for CCA not only via down-regulation of p-mTOR but also degradation
of HIF-1α by VHL and induction of apoptosis by cleaved caspase-3.
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I. Introduction
The mammalian target of rapamycin (mTOR) is a
serine-threonine kinase, identified as the target of rapamycin
which is one of macrolide antibiotics, and is a regulatory
factor in cell division, growth, and survival (Fig. 1) [4, 6,
27]. mTOR is indispensable for the utilization of nutrients to
maintain the survival capacity of the body [27]. Rapamycin
as an mTOR inhibitor suppresses immune responses by
inhibiting lymphocyte proliferation, and has been reported
to suppress rejection on kidney or heart transplantation in
rats [26]. Rapamycin forms a complex with FK506 binding
protein (FKBP12), inhibiting kinase activity associated with
lymphocyte proliferation [5, 7, 8]. Studies in recent years
have shown the inhibitory effects of rapamycin mediated by
vascular endothelial growth factor (VEGF) on angiogenesis
(Fig. 1) [11, 13, 16, 18]. Rapamycin at a dose used for
immunosuppression has been reported to exhibit marked
inhibitory effects on tumor proliferation in metastasis and
implantation models [13]. As its action mechanism, inhibi-
tion of both the proliferation and tube formation of vascular
endothelial cells has been suggested [13]. Hudson et al.
reported that mTOR acts as a positive regulatory factor in
the PI3K-Akt-mTOR pathway, and that mTOR inhibition
leads to inhibition of HIF-1α mRNA translation [14].
Based on such evidence, as a first step, we evaluated
the mechanism of the mTOR-HIF-1 pathway in vitro, andHarasawa et al. 114
then the effectiveness of rapamycin in vivo, which is ex-
pected to be a promising new anti-tumor drug for CCA.
II. Materials and Methods
In vitro
Cell culture
RMG-1, a cultured cell strain derived from human
ovarian CCA, was cultured in Ham’s F-12 medium (Gibco
Co., Grand Island, NY) supplemented with 10% FBS (Gibco
Co., Grand Island, NY) and 1% penicillin-streptomycin
(Gibco Co., Grand Island, NY) at 37°C under 5% CO2.
Drug preparation
As a derivative of rapamycin, everolimus (Certican:
0.25 mg tablet) was purchased from Novartis Pharma
(Basel, Switzerland). For the in vitro study, everolimus
was prepared in dimethylsulfoxide before addition to the
cell cultures. For the in vivo study, everolimus was diluted
at the appropriate concentration in 0.5% carboxymethyl
cellulose just before administration by gavage to the mice.
Immunoblotting
Immunoblotting was used to analyze changes after
everolimus treatment in the expression of mTOR and its
related factors in the downward pathway (Fig. 1). RMG-1
cells were treated with everolimus at 80 nM or 100 nM
for 6 hr. Cell lysates were subjected to SDS-PAGE; a
prestained protein marker (Broad Range, Bio-Rad Laborato-
ries, Hercules, CA, USA) was run on the outside lane to ver-
ify the molecular weight of mTOR, phosphorylated-mTOR
(p-mTOR), phosphorylated-4E-BP1 (p-4E-BP1), HIF-1α,
VEGF, von Hippel-Lindau (VHL) and cleaved caspase-3.
The samples were then transferred to polyvinylidene fluo-
ride membranes, which were blocked with 2% normal goat
serum in 5% skim milk for 1 hr at room temperature (RT).
After incubation overnight at RT with the antibodies as
follows: mTOR (clone 7C10, diluted at 1:1000, Cell Signal-
ing Technology, Beverly, MA, USA), p-mTOR (clone 49F9,
diluted at 1:1000, Cell Signaling Technology), p-4EBP1
(clone 236B4, diluted at 1:1000, Cell Signaling Tech-
nology), HIF-1α (clone H-206, diluted at 1:200, Santa Cruz
Biotech, Santa Cruz, CA, USA), VEGF (clone 5C3F8,
diluted at 1:1000, Novus Biologicals, Littleton, CO, USA),
VHL (clone G-7, diluted at 1:100, Santa Cruz Biotech),
cleaved caspase-3 (clone Asp175, diluted at 1:1000, Cell
Signaling Technology), the membranes were then incubated
with a biotin labeling anti-mouse/-rabbit IgG (Nichirei Bio-
sciences, Tokyo, Japan) and with avidin-horseradish per-
oxidase complex (Vectastain Elite ABC kit, Vector Labora-
tories Inc, Burlingame, CA, USA) or rabbit-labeled polymer
(Envision kit, Dako, Copenhagen, Denmark).
Immunohistochemistry
Treated cells with everolimus at 100 nM and non-
treated cells were smeared on glass slides and fixed in 100%
ethanol. Endogenous peroxidase was then blocked with
methanol containing 0.3% hydrogen peroxidase for 30 min
at RT. These preparations were incubated for 1 hr at RT with
the anti-Ki-67-antibody. The cells grown on the chamber
slides were treated with everolimus at 80 nM, 100 nM for
12 hr and fixed by 4% paraformaldehyde. Then, after
blocking endogenous peroxidase similarly as smear prepa-
ration, these preparations were incubated with the primary
antibodies such as mTOR (diluted at 1:100), p-mTOR
(diluted at 1:100), HIF-1α (diluted at 1:60), VHL (diluted
at 1:50). The secondary detection systems were similarly
used as immunoblotting.
The expressions were semi-quantitatively evaluated
according to the following scoring scheme: –, no staining;
1+, <10% cells positive; 2+, 10%–50% cells positive; 3+,
>50% cells positive.
Fig. 1. mTOR regulation pathway involved in hypoxia.
Everolimus combines with FKBP12, and obstructs the
function of mTOR. p-mTOR (phosphorylated-mTOR)
is inhibited by everolimus. Inhibition of mTOR
increases the binding of 4E-BP1 to elF-4E, conse-
quently leading to inactivation of HIF-1α mRNA trans-
lation. HIF-1 composed of α unit and β unit binds to
hypoxia response elements (HREs), resulting in the
upregulation of hypoxia-related factors such as VEGF
(vascular endothelial growth factor), GLUT-1 (glucose
transporter-1), and EPO (erythropoietin).mTOR Inhibition in Ovarian Carcinoma 115
Cell count
The cells treated with everolimus at 100 nM for 6 hr
were collected and washed with a new medium. The extent
of lyses was measured by a cell-counting chamber stained
with trypan blue.
In vivo
To evaluate the anti-tumor effects, 7 nude mice aged 6
weeks were inoculated subcutaneously in the right flank
with 1×107 RMG-1 cells in 200 μL of PBS. When the tumors
reached approximately 150 mm3 in volume, the nude mice
were orally administered with everolimus (2.5 mg/kg) once
a week for 33 days. As a control, 3 mice were inoculated
with buffered saline.
III. Results
Although mTOR expression did not differ between the
cells treated by everolimus and non-treated cells, p-mTOR
expression was significantly decreased in the treated cells
compared with the non-treated cells (Figs. 2, 3). Analysis of
the expression of mTOR-related factors in the downstream
region revealed a marked decrease in the expressions of
p-4E-BP1, HIF-1α, and VEGF in the treated cells (Figs. 2,
3). However, there was no significant difference between
80 nM and 100 nM. On the other hand, analysis of the influ-
Fig. 3. Down- and upregulation
of mTOR-involved proteins by
immunohistochemistry. m-TOR
did not show a change of expres-
sion at all, but p-mTOR and
HIF-1α expressions completely
attenuated after the treatment.
In contrast, VHL was clearly
expressed at 100 nM (–, no
staining; 1+, <10% cells posi-
tive; 2+, 10%–50% cells posi-
tive; 3+, >50% cells positive).
Fig. 2. Down- and upregulation of mTOR-involved proteins by
immunoblotting. Expressions of p-mTOR, p-4E-BP1, HIF-1α, and
VEGF were almost completely diminished due to treatment with
everolimus. In contrast, the expressions of VHL and cleaved
caspase-3 were strengthened in the treated cells.Harasawa et al. 116
ences of the drug on the HIF-1α degradation system showed
an increase of expression of VHL as a ubiquitin ligase,
which is targeting HIF-1α, in the treated cells (especially at
100 nM) compared with the non-treated cells. Increase of
cleaved caspase-3 expression was shown in the treated cells
(especially at 100 nM).
Ki-67 labeling index was estimated as 11% in the
treated cells but 17% in the non-treated cells. In the analysis
of cell survival, the cell count was 6.6×106 in the treated
cells, but 8.7×106 in the non-treated cells, showing that 25%
of the cells died with the treatment.
In the nude mice implanted with RMG-1 cells, the
treated group showed a decrease in tumor size in 4 of the
7 mice. The tumor disappeared in 2 of the 4 mice (Figs. 4,
5), and decreased in size by 60–70% in the remaining two.
Of the 3 mice not showing a significant decrease in the
tumor size, 2 mice exhibited a decrease after the initial ad-
ministration but no decrease after the second administration.
The tumors subsequently increased in size and eventually
became uncontrollable. In the remaining one, no significant
change in tumor size was observed from the first administra-
tion.
IV. Discussion
In this study, the marked expression of HIF-1-related
factors was initially observed in the CCA strain. Among
them, expression of mTOR was unchangeable, but p-mTOR,
p-4E-BP1, HIF-1α, and VEGF expressions were dose-
dependently inhibited. Everolimus is known to inhibit the
phosphorylation of mTOR, resulting in inhibition of HIF-1α
translation via the downstream effectors. These results
suggest that mTOR is universally present and may be
maintained in a stable state without phosphorylation.
The non-treated cells showed slight expression of
VHL, which suggests that VHL is not activated in this
CCA strain. Loss of heterozygosity at the VHL gene locus
was reported to be frequently detected in ovarian carcinomas
[22]. Therefore, it is speculated that inactivation of VHL
may occur in ovarian carcinomas and be involved in exces-
sive HIF-1α expression. In renal carcinomas, inactivation
of VHL by mutation, deficiency or methylation has been
reported [12, 23, 25]. However, the detailed mechanism of
the overexpression of VHL induced by everolimus remains
to clarified. This phenomenon may play a role in accelera-
tion of degradation of HIF-1α through another unknown
pathway which is directly related with overexpression of
VHL. In future study, it is necessary to explore the mech-
anism of everolimus-induced overexpression of VHL.
The analysis of changes in the expression of apoptosis-
related factor, represented by cleaved caspase-3, showed no
expression in the non-treated cells. Kleinberg et al. reported
cleaved caspase-3 expression in less than 10% of ovarian
Fig. 4. Anti-tumor effects in the model mice depending on dosage.
The contractive tendency of the tumor was seen in the everolimus-
administered group compared with the control group (1, 2, 3: 1st,
2nd, 3rd administration of everolimus). The values express the
average of each group using the relative ratio to the non-adminis-
tered state.
Fig. 5. Anti-tumor effects in the model mouse shown by gross appearance. The tumor recognized by the naked eye before administration of
everolimus (a) was completely diminished after the administration (b).mTOR Inhibition in Ovarian Carcinoma 117
carcinomas [17]. They also evaluated the possible correla-
tion between cleaved caspase-3 and the outcome, and
reported the involvement of high-level cleaved caspase-3
expression in outcome improvement [17]. Our study showed
that mTOR inhibition leads to cleaved caspase-3 over-
expression and a decrease in the viable cells. It is considered
that the effect of mTOR inhibition is also closely related
to cell death by apoptosis. Albert et al. reported an increase
in cleaved caspase-3 expression through the combination of
radiotherapy and mTOR inhibitor administration in breast
cancer [1], but its detailed mechanism has yet to be clarified.
Analysis of the cell growth ability revealed a decrease
in Ki-67 labeling index from 17% in the non-treated cells to
11% in the treated cells. According to Itamochi et al., the
growth ability of CCA is significantly lower compared to
other types of ovarian carcinomas: Ki-67 labeling index,
CCA 18.4%; serous adenocarcinoma 38.8% [15]. Interest-
ingly, a low survival rate in CCA is considered to be related
to the Ki-67 labeling index <18.4% [15]. Wang et al. also
observed a decrease in the Ki-67 labeling index after mTOR
inhibitor administration using a hepatocellular carcinoma
mice model [28]. An increase in p27kip1 protein after mTOR
inhibition has been reported to decrease the activities of
cyclin-dependent kinase 4 (CDK4)/cyclin D and CDK2/
cyclin E. It is speculated that a decrease in the Ki-67 labeling
index is caused by termination of the cell cycle by increasing
p27kip1 protein due to mTOR inhibition [9].
In our previous study with subcutaneous injection of
everolimus to the tumor in mice, a tendency toward a
decrease in tumor volume was observed [20]. The tumor was
histologically degradated in close association with decreases
in the expressions of HIF-1-related factors. In the present
study, subcutaneous injection of everolimus was changed to
its oral administration, and the tumor volume in mice also
tended to decrease. In terms of clinical application, adminis-
tration of mTOR inhibitor is expected to have great anti-
tumor effects on CCA in combination with other chemo-
therapeutic drugs such as cisplatin [3, 24].
Specific-molecule targeting therapy for various tumors
is being conducted as a promising strategy [19, 29]. It is con-
sidered that tumor therapy should be specifically targeted for
each patient according to propensity of the tumor. Instead of
mTOR, overexpression of p-mTOR is a hallmark for the
optimal administration of m-TOR inhibitor [2, 10, 21]. The
detailed analysis of the novel function of mTOR inhibitors,
which is involved in the activation of apoptosis and HIF-1α
degradation system, should be further studied for more
effective administration of mTOR inhibitor.
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